U.S. markets open in 8 hours 52 minutes
  • S&P Futures

    -29.25 (-0.65%)
  • Dow Futures

    -92.00 (-0.27%)
  • Nasdaq Futures

    -182.25 (-1.23%)
  • Russell 2000 Futures

    -6.20 (-0.31%)
  • Crude Oil

    -0.61 (-0.70%)
  • Gold

    -1.20 (-0.07%)
  • Silver

    -0.22 (-0.87%)

    +0.0009 (+0.08%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +1.74 (+7.30%)

    -0.0009 (-0.07%)

    -0.2750 (-0.24%)

    -2,997.51 (-7.16%)
  • CMC Crypto 200

    -77.95 (-7.83%)
  • FTSE 100

    -4.65 (-0.06%)
  • Nikkei 225

    -400.95 (-1.44%)

InfuSystem Holdings, Inc. Announces $5 Million Stock Repurchase Program

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • INFU

MADISON HEIGHTS, MICHIGAN, Sept. 30, 2019 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today announced the Company’s Board of Directors has approved a stock repurchase program authorizing the Company to repurchase up to $5 million of the Company’s outstanding common stock through 2020.

Rich DiIorio, chief executive officer of InfuSystem, said, “The stock repurchase program reflects the Board’s confidence in our business, as we continue to see significant market share expansion across the company. This growth, plus the extension of our offerings into the new infusion and pump-related sectors, is expected to accelerate the improvements to our revenue, AEBITDA, and cash generation. In addition to enabling rapid organic growth, our strong operations and improved visibility allow us to resume stock repurchases that are expected to create substantial incremental value for our shareholders.”

Stock Repurchase Program
Reflecting the Company’s much improved financial position and cash-generating capabilities, the Company’s Board of Directors has approved a stock repurchase program authorizing the Company to repurchase up to $5 million of the Company’s outstanding common stock. The repurchase program will be subject to market conditions, the periodic capital needs of the Company’s operating activities, and the continued satisfaction of all covenants under the Company’s existing credit agreement. Repurchases under the program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The repurchase program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time.

About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, and Ontario, Canada. The Company’s stock is traded on the NYSE American under the symbol INFU.

Forward-Looking Statements
Statements made in this press release that are not historical facts are considered to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "strategy," "future," "likely," variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements include statements relating to future actions, business plans, objectives and prospects, future operating or financial performance and future stock repurchases. In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential changes in overall healthcare reimbursement, including CMS competitive bidding, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and covenants, and other risks associated with our common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company's annual report on Form 10-K for the year ended December 31, 2018 and in other filings made by the Company from time to time with the Securities and Exchange Commission, including our quarterly reports on Form 10-Q. Our annual report on Form 10-K is available on the SEC's EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this press release speak only as of the date hereof. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.

Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.

Joe Dorame, Joe Diaz & Robert Blum
Lytham Partners, LLC